Multiple Hamartoma Syndrome

Multiple Hamartoma Syndrome is a rare genetic condition. It causes many different types of growths (hamartomas) to appear on the body. These growths can be found on the skin, inside the mouth, or in other areas. People with this syndrome have an increased risk of developing certain types of cancer, like breast or thyroid cancer.

ConditionRare Disease

What people with Multiple Hamartoma Syndrome report

Every report comes from a Lived member, sent anonymously.

Have you had Prophylactic Mastectomy for Multiple Hamartoma Syndrome?

NameHow it went

About Multiple Hamartoma Syndrome

What It Is

Multiple hamartoma syndrome is an inherited condition in which noncancerous growths called hamartomas form in the skin, the lining of the mouth, the intestine and other organs. People with it also have a higher than usual lifetime risk of several cancers. When it is caused by a change in the PTEN gene, which is the most common identified cause, doctors call it PTEN hamartoma tumor syndrome (PHTS). Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome, once described as separate disorders, are now understood as different presentations of this same condition. The features vary a great deal, even within one family. Many people have a larger than average head size (macrocephaly) and small, benign bumps on the face, hands or gums that usually become noticeable by the late twenties. Thyroid nodules, intestinal polyps, fatty lumps under the skin and unusual blood vessel growths are also common. Some children have developmental delay or autism, and Bannayan-Riley-Ruvalcaba syndrome is usually recognized in early childhood for these reasons. The condition matters most because of cancer risk. Breast cancer is the most common cancer in women with PHTS, and the risks of thyroid and endometrial (uterine lining) cancer are clearly raised. Kidney cancer, colorectal cancer and melanoma, a serious skin cancer, are also more likely than in the general population. These cancers tend to appear at younger ages, often in a person's thirties or forties.

Causes & Risk Factors

PTEN is a tumor suppressor gene: it normally acts as a brake on how fast cells grow and divide. When one copy does not work properly, that brake is weaker, so benign growths form more easily and some tissues are more prone to becoming cancerous. Many people, often most, who fit the clinical description of Cowden syndrome have no PTEN change found. In some of them a different gene is responsible, in others the cause is not yet known, and their surveillance is planned from their own and their family's history. The condition is inherited in an autosomal dominant pattern, meaning one altered copy of the gene is enough. Each child of an affected parent has a 50% chance of inheriting it. Some people are the first in their family to have it because the gene change arose new in them. Nothing a person did causes the condition, and everyday exposures do not trigger it, although the usual cancer risk factors, such as smoking, heavy alcohol use and obesity, are still worth reducing.

How It's Diagnosed

Diagnosis usually starts when a clinician notices a pattern: for example, a child with a large head and autism or developmental delay, or an adult with characteristic skin bumps, thyroid disease or an early breast or thyroid cancer, or a family history of these. Published clinical criteria combine major and minor features, such as macrocephaly, specific skin findings, intestinal polyps and certain cancers, to decide whether testing is warranted. The diagnosis is confirmed with a genetic blood or saliva test that looks for a harmful variant in PTEN. A positive result is what triggers the formal surveillance plans described below. A negative result does not always rule the condition out: some people with a strong clinical picture have no detectable PTEN change, and their care is planned case by case from their own and their family's history. Once someone is diagnosed, close relatives are offered testing for the same variant. A relative who tests negative can usually follow ordinary population screening, while one who tests positive can begin the extra checks that matter for them.

Treatment Options

There is no treatment that corrects the underlying gene change. Care focuses on finding cancers early, when treatment is most likely to cure them, and on managing benign growths and developmental needs. Because so many organs are involved, care works best when coordinated by a genetics team or a center with PHTS experience. Cancer surveillance is the core of management for people with a confirmed PTEN variant. Recommendations from an international consensus group (2025) and from US and European guidelines broadly agree, though their starting ages differ slightly: Breast: women have a yearly breast MRI starting at age 25 to 30, adding mammography from about age 40. Men are not reported to have a higher breast cancer risk and do not need breast screening. Thyroid: a baseline thyroid ultrasound in adolescence (the international group suggests age 12; some guidelines start earlier or later and repeat it more often), repeated every few years depending on whether nodules are found. Colon: a first colonoscopy at age 35 to 40; repeat intervals then depend on how many polyps are found. Kidney: an ultrasound every two years from about 35 to 40 may be considered. Skin: a skin check by a dermatologist starting between about age 18 and 30, depending on the guideline, with follow-up as the dermatologist advises. There is no proven screening test for endometrial cancer in PHTS, so the main safeguard is reporting abnormal bleeding promptly. Surgery to lower risk is an individual decision. Because breast cancer risk in PHTS appears similar to that seen with BRCA1 and BRCA2 gene changes, guidelines recommend discussing risk-reducing mastectomy (removal of breast tissue) with an experienced high-risk breast team, weighing family history, surgical risks, reconstruction and quality of life. Routine removal of the thyroid or uterus is not recommended for prevention alone. Medicines that aim to prevent cancer or polyps have not been studied well in PHTS and are not routinely recommended. If cancer develops, it is treated with the same standard approaches used for that cancer in anyone else, including chemotherapy and radiation when indicated. Benign growths are treated when they cause symptoms; painful vascular malformations sometimes respond to drugs called mTOR inhibitors, such as sirolimus, which damp down an overactive cell-growth signal (sirolimus is also used after organ transplants), but these are not recommended for preventing cancer or for treating developmental symptoms outside research. Developmental, speech, behavioral and learning support follows the same approaches used for autism and developmental delay in general.

What to Expect

PHTS is lifelong, and the experience differs widely between people. Some children's main challenges are developmental: speech delay, learning differences, autism and sometimes low muscle tone or seizures. Guidelines recommend a developmental and neuropsychological assessment at diagnosis so that school and therapy support can start early, and regular checks for anxiety, depression and sleep problems as children grow. Delays in early childhood may improve with age. In adulthood, the focus shifts to surveillance. Keeping up with yearly and multi-year scans and scopes takes real commitment and coordination, and many people find a single coordinating clinician or a PHTS clinic helps. The raised cancer risk is significant, but published lifetime estimates vary widely and may be overstated, because early studies tended to include the most severely affected families. When cancers are found, outcomes in a large European study were comparable to the same cancers in people without PHTS, and early-stage cancers had high survival. This is the reason surveillance is emphasized, although studies have not yet shown how much it lowers the risk of dying from cancer. Living with an inherited cancer risk, and sometimes passing it on, can be emotionally demanding. Genetic counseling, psychological support and patient organizations such as the PTEN Foundation can help with decisions about testing, family planning and surgery.

When to Seek Help

Ask about genetic evaluation if a child has a notably large head together with autism or developmental delay, or if you or your family have several features of the condition, such as characteristic skin bumps, multiple thyroid nodules, intestinal polyps or breast, thyroid or uterine cancer at a young age. If a relative has a known PTEN variant, ask about testing yourself. If you have PHTS, contact your care team promptly about unexplained or irregular vaginal bleeding or any bleeding after menopause, a new breast or neck lump, a changing mole, or new neurologic symptoms such as weakness, numbness or trouble with balance, which can signal a rare benign growth in the cerebellum (the part of the brain that coordinates movement) or an abnormal blood vessel in the brain. Arrange an assessment for possible seizures or a loss of skills a child had already gained, and for recurrent abdominal cramping or blood in the stool, which can signal polyps. Severe or worsening belly pain with vomiting, a swollen belly, or being unable to pass stool or gas needs same-day medical care, because a polyp can occasionally block the bowel.

Questions to Ask Your Doctor

  1. 1.Which surveillance tests do I need, starting when, and who will coordinate them so nothing is missed?
  2. 2.How do the cancer risk estimates apply to me, given my sex, age and family history?
  3. 3.Should I talk with a high-risk breast specialist about risk-reducing surgery, and what would that decision involve?
  4. 4.Which of my relatives should be offered genetic testing, and how do I tell them?
  5. 5.For my child, what developmental, learning or behavioral assessments and supports should we arrange now?

Last reviewed • Oct 2026

Educational content, not medical advice.